Release
📈 Stocks
Insilico Medicine Targets $36.5B GLP-1 Market With New GIPR Antagonist
(33 minutes ago)
Insilico Medicine advances its drug pipeline with the nomination of ISM1354, aiming to capture market share in the high-growth weight management sector…